O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.

@article{LechaptZalcman2012O6M,
  title={O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.},
  author={Emmanu{\`e}le Lechapt-Zalcman and Gu{\'e}na{\"e}lle Levallet and Audrey Emmanuelle Dugu{\'e} and Anne Vital and M. -D. Diebold and Philippe Menei and Philippe Colin and Philippe Peruzzy and Evelyne Emery and Myriam Bernaudin and Françoise Chapon and Jean S{\'e}bastien Guillamo},
  journal={Cancer},
  year={2012},
  volume={118 18},
  pages={4545-54}
}
BACKGROUND O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation status was proposed as a prognostic biomarker for patients with glioblastoma. However, the prognostic impact of MGMT in patients with newly diagnosed glioblastoma who receive carmustine-releasing wafers (Gliadel) along with temozolomide (TMZ) is still unknown. METHODS MGMT promoter methylation status and protein expression were analyzed in formalin-fixed, paraffin-embedded tumor specimens obtained from 111 French… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Similar Papers

Loading similar papers…